Idec Corp.

Research and Markets Adds Report: Pipeline Insight: Colorectal Cancer.
Health & Beauty Close-Up; 11/17/2009; 871 words; ...pharmaceutical markets. Companies Mentioned: - AstraZeneca PLC - Biogen Idec, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb...Keryx Biopharmaceuticals, Inc. - Merck KGaA - Schering-Plough Corp. Report information: http://www.researchandmarkets...

United States: Biogen Updates Tysabri Label To Reflect Risk With Longer Use.
TendersInfo; 11/9/2009; 756 words; Byline: prashant03 Biogen Idec Inc. (BIIB) amended the U.S. label of multiple sclerosis treatment Tysabri, sold with Elan Corp. PLC (ELN), on Friday to reflect that the risk of a rare brain infection rises with longer usage. The changes...

THE TICKER.(Business)
The Boston Herald; 11/7/2009; 547 words; ...spending and costs associated with its court reorganization. Tysabri warning New prescribing information on Biogen Idec and Elan Corp.'s Tysabri says a brain infection linked to the multiple sclerosis drug is more likely to occur the longer patients...

New label says Tysabri risks increase over time
The Boston Globe; 11/7/2009; 307 words; NEW YORK - A brain infection linked to Biogen Idec Inc. and Elan Corp.'s Tysabri is more likely to occur the longer patients use...rate beyond three years isn't known, according to Biogen Idec spokeswoman Naomi Aoki.

Genentech Earnings Tops Again, But Tarceva Concern Has Impact.
BIOWORLD Today; 11/4/2009; 1744 words; ...business, for God's sake, it isn't a science experiment anymore." Shares of Genentech's Rituxan partner IDEC Pharmaceuticals Corp. (NASDAQ:IDPH) also felt the sting, finishing at $31.59, down $2.35, or 6.92 percent. Genentech...